The Indian Pharmaceutical Alliance's (IPA) quality forum is currently underway in Hyderbad. CNBC-TV18’s Arachana Shukla caught up with the Managing Director of Cadila Healthcare, Sharvil Patel on the sidelines of that forum and asked him about price erosion in the US market.

TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study

Want to significantly expand emerging market business: Cadila

In a rare television appearance, Cadila Healthcare's relatively new Managing Director, Sharvil Patel spoke with CNBC-TV18's Ekta Batra on a whole host of issues including their hope of becoming India's number one oncology player within the next 5 years.

Aim to develop and market molecules in India first: Zydus Cadila

In an interview with CNBC-TV18, Pankaj R Patel, CMD, Zydus Cadila Healthcare, talked about the company's business strategy, progress with molecule research and earnings outlook.

Pricing pressure in US biz cyclical in nature: Cadila Health

In an exclusive interview with CNBC-TV18, Pankaj Patel said that the pricing pressure in US is cyclical in nature and competition is going to exist in the generic medicine market in US.

Indian pharma cos need to step-up safeguards at plants: Handa

In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

No data integrity issue at Moraiya facility: Cadila Health

Pankaj R Patel, CMD, Cadila Healthcare, said there are no data integrity issues with the Moraiya facility. He said the company plans to give additional information to the US FDA to address the Moraiya issue

Indian pharma to revive by Apr; see better margins: Cadila

However, increased inspection is a positive for the industry, opines Pankaj R Patel, chairman and managing director, Zydus Cadila Healthcare. This, despite the fact that the company has received a warning letter from the US regulator.

Zydus Cadila to launch Lipaglyn in other mkts in 3-5 yrs

Cadila's CMD Pankaj Patel says global market size for Lipaglyn type of drug is around USD 29 billion. The drug is expected to be launched in India in Q3 and in other markets in 3-5 years.